SG11201605654QA - Fused heterocyclic compound - Google Patents
Fused heterocyclic compoundInfo
- Publication number
- SG11201605654QA SG11201605654QA SG11201605654QA SG11201605654QA SG11201605654QA SG 11201605654Q A SG11201605654Q A SG 11201605654QA SG 11201605654Q A SG11201605654Q A SG 11201605654QA SG 11201605654Q A SG11201605654Q A SG 11201605654QA SG 11201605654Q A SG11201605654Q A SG 11201605654QA
- Authority
- SG
- Singapore
- Prior art keywords
- heterocyclic compound
- fused heterocyclic
- fused
- compound
- heterocyclic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Reproductive Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Child & Adolescent Psychology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014025832 | 2014-02-13 | ||
| PCT/JP2015/000639 WO2015122187A1 (en) | 2014-02-13 | 2015-02-12 | Fused heterocyclic compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201605654QA true SG11201605654QA (en) | 2016-08-30 |
Family
ID=52589729
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201605654QA SG11201605654QA (en) | 2014-02-13 | 2015-02-12 | Fused heterocyclic compound |
Country Status (39)
| Country | Link |
|---|---|
| US (2) | US9346776B2 (uk) |
| EP (1) | EP3105213B1 (uk) |
| JP (2) | JP6383427B2 (uk) |
| KR (1) | KR102378454B1 (uk) |
| CN (1) | CN105980370B (uk) |
| AR (1) | AR099400A1 (uk) |
| AU (1) | AU2015216438B2 (uk) |
| BR (1) | BR112016018455B1 (uk) |
| CA (1) | CA2938191C (uk) |
| CL (1) | CL2016001911A1 (uk) |
| CR (1) | CR20160367A (uk) |
| CY (1) | CY1121534T1 (uk) |
| DK (1) | DK3105213T3 (uk) |
| DO (1) | DOP2016000206A (uk) |
| EA (1) | EA032201B1 (uk) |
| EC (1) | ECSP16067137A (uk) |
| ES (1) | ES2717113T3 (uk) |
| HR (1) | HRP20190369T1 (uk) |
| HU (1) | HUE042709T2 (uk) |
| IL (1) | IL246838B (uk) |
| JO (1) | JO3472B1 (uk) |
| LT (1) | LT3105213T (uk) |
| MA (1) | MA39246A1 (uk) |
| ME (1) | ME03422B (uk) |
| MX (1) | MX368392B (uk) |
| MY (1) | MY173607A (uk) |
| NZ (1) | NZ722035A (uk) |
| PE (1) | PE20161243A1 (uk) |
| PH (1) | PH12016501582B1 (uk) |
| PL (1) | PL3105213T3 (uk) |
| PT (1) | PT3105213T (uk) |
| RS (1) | RS58498B1 (uk) |
| SG (1) | SG11201605654QA (uk) |
| SI (1) | SI3105213T1 (uk) |
| TR (1) | TR201903892T4 (uk) |
| TW (1) | TWI669297B (uk) |
| UA (1) | UA118280C2 (uk) |
| UY (1) | UY35994A (uk) |
| WO (1) | WO2015122187A1 (uk) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2661895C2 (ru) * | 2013-03-13 | 2018-07-23 | Такеда Фармасьютикал Компани Лимитед | Соединение сложного эфира гуанидинобензойной кислоты |
| US9346776B2 (en) | 2014-02-13 | 2016-05-24 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound |
| US9428470B2 (en) | 2014-02-13 | 2016-08-30 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| WO2015123437A1 (en) | 2014-02-13 | 2015-08-20 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
| SI3105218T1 (sl) | 2014-02-13 | 2019-11-29 | Incyte Corp | Ciklopropilamini kot inhibitorji LSD1 |
| TWI720451B (zh) | 2014-02-13 | 2021-03-01 | 美商英塞特控股公司 | 作為lsd1抑制劑之環丙胺 |
| WO2016007722A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| US9695168B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted imidazo[1,5-α]pyridines and imidazo[1,5-α]pyrazines as LSD1 inhibitors |
| WO2016007736A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Imidazopyrazines as lsd1 inhibitors |
| JP2018080109A (ja) * | 2015-03-16 | 2018-05-24 | 武田薬品工業株式会社 | 治療剤 |
| WO2016158788A1 (ja) * | 2015-03-27 | 2016-10-06 | 武田薬品工業株式会社 | 縮合複素環化合物 |
| AU2016243939B2 (en) | 2015-04-03 | 2020-09-03 | Incyte Holdings Corporation | Heterocyclic compounds as LSD1 inhibitors |
| PE20181175A1 (es) | 2015-08-12 | 2018-07-20 | Incyte Corp | Sales de un inhibidor de lsd1 |
| CA3081564A1 (en) | 2017-11-02 | 2019-05-09 | Ube Industries, Ltd. | Double-headed protease inhibitor |
| SG11202011083PA (en) * | 2018-05-09 | 2020-12-30 | Lg Chemical Ltd | Novel compound exhibiting enteropeptidase inhibitory activity |
| TW202024028A (zh) | 2018-08-27 | 2020-07-01 | 日商思可海雅藥品股份有限公司 | 苯甲酸酯化合物 |
| US10968200B2 (en) | 2018-08-31 | 2021-04-06 | Incyte Corporation | Salts of an LSD1 inhibitor and processes for preparing the same |
| US20220281866A1 (en) | 2019-07-19 | 2022-09-08 | Janssen Pharmaceutica Nv | 5,8-disubstituted-[1,2,4]triazolo[1,5-a]pyridinyl and 5,8-disubstituted-imidazo[1,2-a]pyridine derivatives useful as inhibitors of enteropeptidase |
| JP7327788B2 (ja) * | 2019-08-06 | 2023-08-16 | 学校法人福岡大学 | 糖化産物生成抑制剤及び医薬組成物 |
| WO2021166899A1 (ja) * | 2020-02-17 | 2021-08-26 | 宇部興産株式会社 | インクレチン様物質と組み合わせて使用するための消化管プロテアーゼ阻害剤を含む薬剤 |
| CN111544599B (zh) * | 2020-07-10 | 2020-12-01 | 有术肌肤管理(深圳)有限公司 | 一种用于治疗痤疮的化合物及其用于制备药物或化妆品的用途 |
| CN111803652B (zh) * | 2020-08-04 | 2021-09-14 | 南通康是美生物科技有限公司 | 治疗痤疮的化合物在制备治疗痤疮的药物组合物或化妆品组合物中的用途 |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5289640A (en) | 1976-01-21 | 1977-07-27 | Ono Pharmaceut Co Ltd | Guanidinobenzoic acid derivatives, and antiplasmin agents and remedies for pancreas diseases containing the said guanidinobensolc acid deriv atives |
| AU527371B2 (en) | 1980-09-16 | 1983-03-03 | Torii & Co., Ltd. | Amidine |
| JPS5753454A (en) | 1980-09-16 | 1982-03-30 | Torii Yakuhin Kk | Guanidinobenzoate and anticomplementary agent |
| US5116985A (en) | 1989-12-28 | 1992-05-26 | Snow Brand Milk Products Co., Ltd. | Isoquinoline derivatives and salts thereof |
| JP2886586B2 (ja) | 1989-12-28 | 1999-04-26 | 雪印乳業株式会社 | 新規グアニジノ安息香酸誘導体及びその酸付加塩 |
| JPH0446148A (ja) | 1990-06-08 | 1992-02-17 | Asahi Chem Ind Co Ltd | ４―グアニジノ安息香酸フェニルエステル誘導体およびそれらを含有する蛋白分解酵素阻害剤 |
| JPH06192085A (ja) | 1992-08-31 | 1994-07-12 | Yuji Inada | ダニアレルギー治療剤 |
| EP0673924A4 (en) | 1992-12-10 | 1996-04-24 | Teikoku Chem Ind Co Ltd | PROPRIONIC ACID DERIVATIVE. |
| JPH0753500A (ja) | 1993-08-16 | 1995-02-28 | Sanwa Kagaku Kenkyusho Co Ltd | グアニジノ安息香酸誘導体及びこれらを有効成分とする蛋白分解酵素阻害剤 |
| JPH0848664A (ja) | 1994-08-05 | 1996-02-20 | Hisamitsu Pharmaceut Co Inc | 新規なグアニジノ安息香酸エステル誘導体 |
| WO1997010224A1 (en) | 1995-09-13 | 1997-03-20 | Takeda Chemical Industries, Ltd. | Benzoxazepine compounds, their production and use as lipid lowering agents |
| JPH09124571A (ja) | 1995-11-01 | 1997-05-13 | Japan Tobacco Inc | アミド化合物及びその用途 |
| US6388122B1 (en) | 1996-04-10 | 2002-05-14 | Ono Pharmaceutical Co., Ltd. | Tryptase inhibitor and novel guanidino derivatives |
| JPH10101556A (ja) | 1996-09-27 | 1998-04-21 | Ono Pharmaceut Co Ltd | ファクターｄ阻害剤 |
| JPH10251239A (ja) | 1997-03-14 | 1998-09-22 | Mochida Pharmaceut Co Ltd | 新規４ｈ−３，１−ベンゾオキサジン−４−オン誘導体 |
| JPH10306025A (ja) | 1997-05-07 | 1998-11-17 | Touin Yokohama Univ | 花粉プロテアーゼ阻害剤 |
| AR035016A1 (es) | 1999-08-25 | 2004-04-14 | Takeda Chemical Industries Ltd | Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima. |
| EP1302462A4 (en) | 2000-07-17 | 2007-07-18 | Takeda Pharmaceutical | Sulphonic derivatives, process for their preparation and their use |
| WO2004039365A1 (en) | 2002-11-01 | 2004-05-13 | Takeda Pharmaceutical Company Limited | Agent for preventing or treating neuropathy |
| EP1559422B1 (en) | 2002-11-08 | 2014-04-30 | Takeda Pharmaceutical Company Limited | Receptor function controlling agent |
| AU2003284596A1 (en) | 2002-11-22 | 2004-06-18 | Takeda Pharmaceutical Company Limited | Imidazole derivative, process for producing the same, and use |
| WO2004106276A1 (ja) | 2003-05-30 | 2004-12-09 | Takeda Pharmaceutical Company Limited | 縮合環化合物 |
| US7534887B2 (en) | 2003-09-30 | 2009-05-19 | Takeda Pharmaceutical Company Limited | Thiazoline derivative and use of the same |
| US7820673B2 (en) | 2003-12-17 | 2010-10-26 | Takeda Pharmaceutical Company Limited | Urea derivative, process for producing the same, and use |
| TW200523247A (en) | 2003-12-25 | 2005-07-16 | Takeda Pharmaceutical | 3-(4-benzyloxyphenyl) propanoic acid derivatives |
| US7585880B2 (en) | 2003-12-26 | 2009-09-08 | Takeda Pharmaceutical Company Limited | Phenylpropanoic acid derivatives |
| WO2005087710A1 (ja) | 2004-03-15 | 2005-09-22 | Takeda Pharmaceutical Company Limited | アミノフェニルプロパン酸誘導体 |
| EP1731505B1 (en) | 2004-03-30 | 2015-01-14 | Takeda Pharmaceutical Company Limited | Alkoxyphenylpropanoic acid derivatives |
| TWI396686B (zh) | 2004-05-21 | 2013-05-21 | Takeda Pharmaceutical | 環狀醯胺衍生物、以及其製品和用法 |
| WO2006057152A1 (ja) | 2004-11-08 | 2006-06-01 | Ono Pharmaceutical Co., Ltd. | タンパク質分解酵素阻害化合物からなる糖尿病治療剤 |
| EP1843819A2 (en) | 2004-11-15 | 2007-10-17 | Obe Therapy Biotechnology S.A.S. | Methods of reducing body fat |
| ATE401007T1 (de) | 2004-11-26 | 2008-08-15 | Nutricia Nv | Kleinkindernahrung mit proteasehemmer |
| JP5094394B2 (ja) | 2005-04-20 | 2012-12-12 | 武田薬品工業株式会社 | 縮合複素環化合物 |
| JP2006348023A (ja) * | 2005-05-17 | 2006-12-28 | Santen Pharmaceut Co Ltd | アミン誘導体を有効成分として含む血管新生阻害剤 |
| WO2007013694A1 (ja) | 2005-07-29 | 2007-02-01 | Takeda Pharmaceutical Company Limited | フェノキシアルカン酸化合物 |
| JP5084503B2 (ja) | 2005-07-29 | 2012-11-28 | 武田薬品工業株式会社 | シクロプロパンカルボン酸化合物 |
| KR20080033524A (ko) | 2005-08-10 | 2008-04-16 | 다케다 야쿠힌 고교 가부시키가이샤 | 당뇨병 치료제 |
| JP2007063225A (ja) | 2005-09-01 | 2007-03-15 | Takeda Chem Ind Ltd | イミダゾピリジン化合物 |
| AU2007208495A1 (en) * | 2006-01-12 | 2007-08-02 | Merck Sharp & Dohme Corp. | Hydroxyalkylarylamide derivatives |
| GEP20115359B (en) | 2006-06-27 | 2011-12-26 | Takeda Pharmaceutical | Fused cyclic compounds |
| US8492405B2 (en) | 2006-10-18 | 2013-07-23 | Takeda Pharmaceutical Company Limited | Glucokinase-activating fused heterocyclic compounds and methods of treating diabetes and obesity |
| US7652133B2 (en) | 2006-10-19 | 2010-01-26 | Takeda Pharmaceutical Company Limited | Indole compound |
| US20100016396A1 (en) | 2007-01-29 | 2010-01-21 | Hiroshi Imoto | Pyrazole compound |
| WO2008099794A1 (en) | 2007-02-09 | 2008-08-21 | Takeda Pharmaceutical Company Limited | Fused ring compounds as partial agonists of ppar-gamma |
| JPWO2008136428A1 (ja) | 2007-04-27 | 2010-07-29 | 武田薬品工業株式会社 | 含窒素５員複素環化合物 |
| WO2008156757A1 (en) | 2007-06-19 | 2008-12-24 | Takeda Pharmaceutical Company Limited | Indazole compounds for activating glucokinase |
| DK2225261T3 (en) | 2007-12-03 | 2016-06-06 | Obe Therapy Biotechnology | Borpeptidinhibitorer of enteropeptidase and their uses in the treatment of obesity, obesity and / or disorders associated with abnormal lipid metabolism |
| EP2511271B1 (en) | 2009-12-07 | 2015-01-21 | Ajinomoto Co., Inc. | Heteroarylcarboxylic acid ester derivative |
| JP5959116B2 (ja) | 2011-06-07 | 2016-08-02 | Ｅａファーマ株式会社 | ヘテロ環カルボン酸エステル誘導体 |
| CN103796992B (zh) | 2011-09-15 | 2016-04-27 | 安斯泰来制药株式会社 | 胍基苯甲酸化合物 |
| WO2013102899A1 (en) | 2012-01-03 | 2013-07-11 | Oramed Ltd. | Methods and compositions for treating diabetes |
| US9024044B2 (en) | 2012-06-14 | 2015-05-05 | Ajinomoto Co., Inc. | Heteroarylcarboxylic acid ester derivative |
| WO2014106846A2 (en) | 2013-01-03 | 2014-07-10 | Oramed Ltd. | Methods and compositions for treating nafld, hepatic steatosis, and sequelae thereof |
| CN105164121A (zh) | 2013-03-08 | 2015-12-16 | 美国安进公司 | 作为β分泌酶抑制剂的全氟化环丙基稠合的1,3-噁嗪-2-胺化合物以及其使用方法 |
| RU2661895C2 (ru) * | 2013-03-13 | 2018-07-23 | Такеда Фармасьютикал Компани Лимитед | Соединение сложного эфира гуанидинобензойной кислоты |
| BR112015031864B1 (pt) | 2013-06-21 | 2022-02-15 | Myokardia, Inc | Compostos de pirimidinadiona contra as condições cardíacas, composição farmacêutica e uso |
| SI3105218T1 (sl) | 2014-02-13 | 2019-11-29 | Incyte Corp | Ciklopropilamini kot inhibitorji LSD1 |
| TWI720451B (zh) | 2014-02-13 | 2021-03-01 | 美商英塞特控股公司 | 作為lsd1抑制劑之環丙胺 |
| US9428470B2 (en) | 2014-02-13 | 2016-08-30 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| US9346776B2 (en) | 2014-02-13 | 2016-05-24 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound |
-
2015
- 2015-02-11 US US14/619,489 patent/US9346776B2/en active Active
- 2015-02-12 RS RS20190324A patent/RS58498B1/sr unknown
- 2015-02-12 PE PE2016001239A patent/PE20161243A1/es unknown
- 2015-02-12 SI SI201530626T patent/SI3105213T1/sl unknown
- 2015-02-12 PL PL15706546T patent/PL3105213T3/pl unknown
- 2015-02-12 KR KR1020167025277A patent/KR102378454B1/ko active IP Right Grant
- 2015-02-12 UY UY0001035994A patent/UY35994A/es not_active Application Discontinuation
- 2015-02-12 SG SG11201605654QA patent/SG11201605654QA/en unknown
- 2015-02-12 US US15/117,538 patent/US9969705B2/en active Active
- 2015-02-12 AR ARP150100411A patent/AR099400A1/es active IP Right Grant
- 2015-02-12 BR BR112016018455-6A patent/BR112016018455B1/pt active IP Right Grant
- 2015-02-12 EP EP15706546.7A patent/EP3105213B1/en active Active
- 2015-02-12 CA CA2938191A patent/CA2938191C/en active Active
- 2015-02-12 TW TW104104693A patent/TWI669297B/zh active
- 2015-02-12 CN CN201580007800.9A patent/CN105980370B/zh active Active
- 2015-02-12 CR CR20160367A patent/CR20160367A/es unknown
- 2015-02-12 LT LTEP15706546.7T patent/LT3105213T/lt unknown
- 2015-02-12 AU AU2015216438A patent/AU2015216438B2/en active Active
- 2015-02-12 MA MA39246A patent/MA39246A1/fr unknown
- 2015-02-12 JO JOP/2015/0028A patent/JO3472B1/ar active
- 2015-02-12 HU HUE15706546A patent/HUE042709T2/hu unknown
- 2015-02-12 TR TR2019/03892T patent/TR201903892T4/tr unknown
- 2015-02-12 PT PT15706546T patent/PT3105213T/pt unknown
- 2015-02-12 NZ NZ722035A patent/NZ722035A/en unknown
- 2015-02-12 WO PCT/JP2015/000639 patent/WO2015122187A1/en active Application Filing
- 2015-02-12 MY MYPI2016702925A patent/MY173607A/en unknown
- 2015-02-12 JP JP2016550664A patent/JP6383427B2/ja active Active
- 2015-02-12 DK DK15706546.7T patent/DK3105213T3/en active
- 2015-02-12 ME MEP-2019-89A patent/ME03422B/me unknown
- 2015-02-12 ES ES15706546T patent/ES2717113T3/es active Active
- 2015-02-12 EA EA201691619A patent/EA032201B1/ru not_active IP Right Cessation
- 2015-02-12 MX MX2016010559A patent/MX368392B/es active IP Right Grant
- 2015-12-02 UA UAA201609351A patent/UA118280C2/uk unknown
-
2016
- 2016-07-19 IL IL246838A patent/IL246838B/en active IP Right Grant
- 2016-07-28 CL CL2016001911A patent/CL2016001911A1/es unknown
- 2016-08-10 PH PH12016501582A patent/PH12016501582B1/en unknown
- 2016-08-11 DO DO2016000206A patent/DOP2016000206A/es unknown
- 2016-08-11 EC ECIEPI201667137A patent/ECSP16067137A/es unknown
-
2018
- 2018-08-03 JP JP2018146459A patent/JP6529649B2/ja active Active
-
2019
- 2019-02-26 HR HRP20190369TT patent/HRP20190369T1/hr unknown
- 2019-03-27 CY CY20191100356T patent/CY1121534T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201807249B (en) | Heterocyclic compound | |
| IL246838A0 (en) | A fused heterocyclic compound | |
| HK1223100A1 (zh) | 雜環化合物 | |
| IL247018A0 (en) | Heterocyclic compound | |
| EP3187497A4 (en) | Heterocyclic compound | |
| IL248991B (en) | Converted dihydroisoquinolinone compounds | |
| EP3205645A4 (en) | Heterocyclic compound | |
| EP3192791A4 (en) | Heterocyclic compound | |
| IL285105A (en) | Heterocyclic compound | |
| EP3133075A4 (en) | Fused heterocyclic compound | |
| EP3110819A4 (en) | Heterocyclic compounds | |
| HRP20190121T1 (hr) | Novi kondenzirani imidazo benzothiazole spojevi | |
| EP3275874A4 (en) | Fused heterocyclic compound | |
| EP3239150A4 (en) | Heterocyclic compound | |
| SI3159335T1 (sl) | Nova heterociklična spojina | |
| IL254890A0 (en) | The tercyclic compound | |
| GB201416351D0 (en) | Heterocyclic derivatives | |
| EP3210971A4 (en) | Heterocyclic compound | |
| IL266099A (en) | Heterocyclic composition |